IRobot (IRBT) Benefits From Strong Footing In Key Markets
Zacks Investment Research | May 28, 2019 04:12AM ET
On May 28, we issued an updated research report on iRobot Corporation (NASDAQ:IRBT) .
In the past year, this Zacks Rank #2 (Buy) stock has gained 36.9%, against the industry ’s decline of 10.9%.
Existing Scenario
Strong demand for products like Roomba i7 in the overseas end markets along with i7/i7+ Roomba sales will continue to drive iRobot’s near-term revenues. The company anticipates that innovation investments, diverse product portfolio and increasing international businesses will boost the top line. Notably, the company expects to generate revenues in the range of $1.28-$1.31 billion (with estimated year-over-year growth rate of 17-20%) in 2019.
Also, the company is raising global household adoption rates of Roomba and Braava products through sales and marketing programs. In addition, the company has rolled out its robotic lawnmower, Terra, in January 2019.
The product is equipped with wire-free beacon system, Imprint Smart Mapping technology and iRobot HOME app. It is predicted to reinvent the lawn-cutting process. The company expects that marketing investments along with new product launches will continue to drive the top line in the quarters ahead.
Moreover, the company announced an increase to existing revolving credit facility (in July 2018) from $75 million to $150 million and extended its term to 2023. This will enable it to execute growth strategy. Notably, the new revolving line of credit facility will provide the company with greater financial flexibility for strategic acquisitions as well as future marketing and product innovation programs.
Other Key Picks
Some other top-ranked stocks in the same space are Dover Corp. (NYSE:DOV) , Tetra Tech, Inc (NASDAQ:TTEK) and Flowserve Corp. (NYSE:FLS) . All the stocks carry a Zacks Rank #2. You can see .
Dover surpassed estimates in each of the trailing four quarters, the average positive earnings surprise being 8.61%.
Tetra Tech surpassed estimates in each of the trailing four quarters, the average positive earnings surprise being 8.22%.
Flowserve outpaced estimates twice in the preceding four quarters, the average earnings surprise being 0.49%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Get The News You Want
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.